We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted pr... Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies. Its drug candidate from E3 ligase inhibitor portfolio, NX-1607, is an orally available CBL-B inhibitor for immuno-oncology indications. Show more
Ask ADVFN Intelligence (AI)
SAN FRANCISCO, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to...
SAN FRANCISCO, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to...
Durable responses are rapid and deepen on treatment as demonstrated by an initial 75.5% Objective Response Rate which increased to 84.2% in patients with at least two disease assessments...
SAN FRANCISCO, Dec. 02, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to...
| Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -1.27 | -6.50948231676 | 19.51 | 20.2 | 18.22 | 597135 | 19.41979386 | CS |
| 4 | -2.16 | -10.5882352941 | 20.4 | 21.67 | 18.22 | 804475 | 19.78234019 | CS |
| 12 | -6.44 | -26.0940032415 | 24.68 | 29.56 | 18.22 | 895139 | 22.82208449 | CS |
| 26 | -2.75 | -13.1014768938 | 20.99 | 29.56 | 17.6253 | 797723 | 22.87403697 | CS |
| 52 | 8.49 | 87.0769230769 | 9.75 | 29.56 | 7.65 | 882816 | 18.36511143 | CS |
| 156 | -8.9 | -32.7929255711 | 27.14 | 29.56 | 4.22 | 596078 | 14.73342305 | CS |
| 260 | -2.01 | -9.92592592593 | 20.25 | 52.38 | 4.22 | 511288 | 18.47056857 | CS |
Monksdream
3 months ago
Monksdream
3 months ago
Monksdream
4 months ago
Monksdream
6 months ago
Monksdream
7 months ago
Monksdream
7 months ago
Monksdream
9 months ago
Monksdream
9 months ago
Monksdream
10 months ago
TheFinalCD
2 years ago
infamous
4 years ago
Phosphene
4 years ago
Phosphene
4 years ago
Phosphene
4 years ago
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
